vertex
-
DATABASE (3)
-
ARTICLES (4)
As part of Vertex Ventures Holdings, a member of Temasek Holdings and Singapore's oldest and largest venture capital firm, Vertex Ventures China focuses on investment in high-growth internet and technology startups across mainland China. Vertex Ventures Holdings has a capital of US$600 million. It also has offices in Singapore, the US and Israel; and investments in these regions as well as Asia.
As part of Vertex Ventures Holdings, a member of Temasek Holdings and Singapore's oldest and largest venture capital firm, Vertex Ventures China focuses on investment in high-growth internet and technology startups across mainland China. Vertex Ventures Holdings has a capital of US$600 million. It also has offices in Singapore, the US and Israel; and investments in these regions as well as Asia.
AddVentures is the venture capital arm of the Siamese Cement Group (SCG), a Thai conglomerate of businesses. The VC focuses on industrial and B2B startups. Besides backing startups, it has also invested in Vertex Ventures (Temasek's venture arm) and the B2B-focused Wavemaker Partners. AddVentures offers the opportunity for its portfolio companies to build synergies with SCG companies and other long-term partnership schemes.
AddVentures is the venture capital arm of the Siamese Cement Group (SCG), a Thai conglomerate of businesses. The VC focuses on industrial and B2B startups. Besides backing startups, it has also invested in Vertex Ventures (Temasek's venture arm) and the B2B-focused Wavemaker Partners. AddVentures offers the opportunity for its portfolio companies to build synergies with SCG companies and other long-term partnership schemes.
Jeffrey Leiden is a physician and scientist of more than 40 years, who is currently the executive chairman of US-based multinational biotech company Vertex Pharmaceuticals. Leiden is also the chairman of Casana, a remote healthcare platform and the chairman of Tmunity, a biotech dedicated to T-cell research. In March 2021, he participated as an angel investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Jeffrey Leiden is a physician and scientist of more than 40 years, who is currently the executive chairman of US-based multinational biotech company Vertex Pharmaceuticals. Leiden is also the chairman of Casana, a remote healthcare platform and the chairman of Tmunity, a biotech dedicated to T-cell research. In March 2021, he participated as an angel investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Indonesia 2021 outlook: VCs "cautiously optimistic" on Southeast Asia's largest country
Investors expect Indonesian startups to regain their growth opportunities when the economy reopens with the Covid-19 vaccine rollout, even as some online living and working habits have stuck
CoRTP: Building sustainable supply chains with returnable packaging
The Shanghai-based startup’s award-winning returnable transit packaging reduced carbon emissions in 2020 by 250,000 tons, and the figure is estimated to reach 8m by 2030
Warung Pintar: Creating a little place of happiness with smart kiosks
CEO Agung Bezharie Hadinegoro on how Warung Pintar is tapping IoT and other digital tech to unleash the economic potential of Indonesia's traditional street vendors
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Sorry, we couldn’t find any matches for “vertex”.
